Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Etafenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.53 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.53 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 14/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etafenone SCHEMBL29846308 | 1.00 | ABCB1 (0.66) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| Etafenone SCHEMBL29406308 | 0.99 | ABCB1 (0.67) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| Etafenone SCHEMBL77987 | 0.99 | ABCB1 (0.67) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| Etafenone SCHEMBL1651223 | 0.96 | ABCB1 (0.65) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10426054 | 0.85 | ABCB1 (0.52) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| Etafenone SCHEMBL13724598 | 0.83 | ABCB1 (0.53) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11671640 | 0.83 | ALDH1A1 (0.74) | ABCB1KDM4EALDH1A1LMNAMEN1 | |
| Etafenone SCHEMBL28142810 | 0.82 | ABCB1 (0.52) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL11338177 | 0.81 | ALDH1A1 (0.76) | ABCB1TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10425940 | 0.80 | MCHR1 (0.50) | ABCB1TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| JP-63017821-A | — | — | None | — | — | JP | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4606435-A2 | PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE BASIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4316598-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY SOLUBLE BASIC AGENT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4316598-A2 | PHARMACEUTICAL COMPOSITION CONTAINING POORLY-SOLUBLE BASIC MEDICINE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-3815688-B1 | PHARMACEUTICAL COMPOSITION CONTAINING POORLY-SOLUBLE BASIC MEDICINE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2023-12-06 | — | — | EP | disclosed |
| US-4892740-A | DRUG COATED WITH POLYMER SOLUBLE IN GASTRIC JUICE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| US-4814176-A | CHITIN OR CHITOSAN, ANIONIC POLYMER, DRUG | TEIJIN LTD. (JP) | 1989-03-21 | — | — | US | disclosed |
| EP-0294103-A1 | A sustained-release preparation and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0277042-A2 | Orally administrable pharmaceutical preparation of improved flavoring characteristics | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1988-08-03 | — | — | EP | disclosed |
| US-4755544-A | Sustained release preparation | TEIJIN LIMITED (JP) | 1988-07-05 | — | — | US | disclosed |
| JP-S6317821-A | FLAVORING ORAL PHARMACEUTICAL | TAISHO PHARMACEUT CO LTD | 1988-01-25 | — | — | JP | disclosed |
| EP-0207638-A2 | Sustained-release pharmaceutical preparation | TEIJIN LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
| EP-0187703-A2 | Sustained release preparation | TEIJIN LIMITED (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | DRD2 1269/4885DRD1 2088/4885DRD3 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.